Analysts Set Expectations for Vaxcyte FY2025 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Vaxcyte in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen expects that the company will earn ($7.02) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Vaxcyte’s current full-year earnings is ($4.14) per share.

A number of other brokerages have also recently issued reports on PCVX. The Goldman Sachs Group began coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective for the company. Needham & Company LLC restated a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $145.71.

Vaxcyte Stock Performance

Shares of PCVX opened at $86.64 on Thursday. The firm has a market cap of $10.80 billion, a PE ratio of -18.83 and a beta of 0.98. Vaxcyte has a twelve month low of $58.10 and a twelve month high of $121.06. The firm’s 50 day moving average price is $87.29 and its 200 day moving average price is $93.88.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same period last year, the business earned ($0.91) earnings per share.

Institutional Investors Weigh In On Vaxcyte

A number of hedge funds have recently added to or reduced their stakes in the stock. Riverview Trust Co bought a new position in Vaxcyte in the 3rd quarter valued at $27,000. Blue Trust Inc. lifted its position in Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after purchasing an additional 93 shares during the period. Meeder Asset Management Inc. boosted its stake in shares of Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after purchasing an additional 635 shares during the last quarter. Nomura Asset Management Co. Ltd. acquired a new stake in shares of Vaxcyte during the 3rd quarter worth approximately $92,000. Finally, Signaturefd LLC raised its stake in shares of Vaxcyte by 51.9% during the third quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock worth $120,000 after buying an additional 358 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Insiders Place Their Bets

In related news, COO Jim Wassil sold 8,000 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $106.80, for a total value of $854,400.00. Following the completion of the sale, the chief operating officer now owns 205,695 shares in the company, valued at approximately $21,968,226. This trade represents a 3.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the sale, the director now directly owns 7,175 shares in the company, valued at approximately $610,664.25. This trade represents a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 85,982 shares of company stock valued at $8,108,425 in the last three months. Company insiders own 3.10% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.